Frost.com - Healthcare Research http://www.frost.com/c/10024/home.do http://www.frost.com/c/10024/home.do - Healthcare Research Frost & Sullivan Unveiling the Potential of Novel Life Sciences Platforms in Stem Cells, Microbiome, Computational Genomics, and Advanced Diagnostics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D759-00-01-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D759-00-01-00-00 The Life Science, Health & Wellness TOE depicts the current landscape and the new life sciences trends across twelve groundbreaking drug discovery and genetic platforms. Each and every platform is accurately profiled covering the most cutting-edge technologies energizing the pharmaceutical landscape, such as stem cells, gene therapy, personalized genomics, computational biology, and non-invasive diagnostics, among others. The TOE also provides information on clinical trials for stem cells in the US. The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Stemgene, human embryonic stem cells, induced pluripotent stem cells, DNA testing, computational genomics, microbiome, hearing aid, cytokine release syndrome Fri, 12 Oct 2018 00:00:00 +0100 Growth Opportunities in the Global Liquid Biopsy Market, 2018 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K294-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K294-01-00-00-00 Liquid biopsy (CTCs and ctDNAs) is slowly gaining momentum in clinical care given its advantages over the traditional tissue-based gold standard methods. Short-term applications in cancer care range from risk assessment to cancer recurrence monitoring. Despite the proven advantages, there is still a significant number of barriers to adoption such as high cost of next-generation sequencing (NGS), reimbursement scenario and the establishment of clinical utility of mutation and clinical evidence. Liquid biopsy remains an interesting business opportunity for several investors and the quest for the most successful company continues. With GRAIL announcing over $1.3 billion in financing, the modality has also garnered interest from several pharma companies vying to capture their share of the market by co-developing drugs and diagnostic products. CTCs and ctDNAs have extended applications across oncology, NIPT (non-invasive prenatal testing), transplant diagnostics and infectious diseases. This report provides a strategic insight into liquid biopsy test makers relating to the challenges they will encounter and lists some of the winning strategies to gain reimbursement and market access. It also highlights growth opportunities where companies can gain the first-mover advantage, and provides a guidance for investment bankers on the most successful and unique disruptive technology. It is important to identify winning strategies in order to be successful. Given the tricky nature of this market, establishing clinical utility and clinical evidence and getting the test into guidelines are some of the key pathways for success. This report discusses regional challenges, regulatory barriers in the UK, China and the US. Key drivers would include the following: Identifying the area of unmet need; aiming for incorporating the test within guidelines and screening programs; overcoming regulatory and reimbursement barriers; and innovating to draw maximum capital from investors. Broadly three types of companies form the competitive landscape in this market - liquid biopsy kit providers, liquid biopsy instrument providers. Most activity is sensed within liquid biopsy as a service model . Currently, there are no clear guidelines that provide a definitive regulatory/ reimbursement roadmap in emerging countries such as India where the concept is still in its nascent stages. Top market trends include: Increasing interest from pharma companies forging partnerships with diagnostic test developers to advance their drug discovery and development activities. Companies are leaning towards biomarkers that are listed in the NCCN guidelines as a low-risk approach and which offer more guaranteed reimbursement. Biomarker tests are focusing on multi-gene or multi-cancer testing rather than a single gene approach. Companies are pushing the boundaries beyond oncology testing. Fri, 5 Oct 2018 00:00:00 +0100 Disrupting Technologies in Infectious Disease Point-of-Care Testing http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298789102 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298789102 Mon, 1 Oct 2018 05:32:09 +0100 Emerging innovations in India http://www.frost.com/prod/servlet/sublib/display-report.do?id=D874-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D874-01-00-00-00 This report "Emerging innovations in India" focuses on recent innovations in India in the fields of chemicals and materials, energy and environment, electronics and automation, healthcare, information and communications. Some topics covered are Cloud Computing-based Management Solution, Robotics in Manufacturing and Agriculture, 3DP Innovations , Automation and Electronics Technologies, Super-engineered Polymers and Biotechnologies, etc. Sat, 29 Sep 2018 00:00:00 +0100 Digital Innovations Creating an Immersive Environment for Health Monitoring http://www.frost.com/prod/servlet/sublib/display-report.do?id=D846-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D846-01-00-00-00 A digital ecosystem in which sensors play a central role, particularly the use of micro- and nano-sensors that can detect a host of biological, organic and inorganic substances, and communicate their detection to a smartphone or a communication system in real-time. This would enable a seamless digital world in which detection of particulate matter which could be potentially harmful can be detected accurately and quickly so that due action can be taken. TechVision's latest medical devices report scans the innovation landscape pertaining to digital technologies. This report analyzes the advances made in these technology areas, and how they are collectively propelling medical diagnostics and health monitoring forward. Fri, 28 Sep 2018 00:00:00 +0100 Innovations in AR-based Surgical Imaging, Mobile X-ray, Rapid Diagnostic Tests, and Image-guided Radiation Therapy http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-24-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-24-00-00 The latest issue of Medical Imaging and Diagnostics TOE profiles innovations in the medical imaging and diagnostics industry. Some of the profiles covered include development of an augmented reality-based surgical imaging, mobile X-ray, rapid diagnostic tests, nano-particle for detecting deep tissue diseases, a hand-held intra-oral X-ray system, and an image-guided radiation therapy. Medical Imaging and Diagnostics TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Augmented reality, surgical imaging, mobile X-ray, rapid diagnostic tests, nanoparticle, deep tissue diseases, hand-held intra-oral X-ray system, image-guided radiation therapy Fri, 28 Sep 2018 00:00:00 +0100 Technology Innovations Enabling Precision Robotic Surgery http://www.frost.com/prod/servlet/sublib/display-report.do?id=D86B-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D86B-01-00-00-00 This research service offers a strategic perspective of the customer, product, technology and competitors that are influencing the global market for surgical robotics. The report is split into three major sections, each focusing on industry overview, competitive landscape, and voice of stakeholder analysis. The report also includes sections for technology and product segmentation, examining the level the influence of technologies across various product portfolios. The report features an exclusive section on designing the operating theatre of the future, which highlights some of the use cases of advanced technologies being adopted along with surgical robotic systems currently in use across leading healthcare facilities worldwide. 1. To strategically review the role played by NPD (new product development) and research and development (R&D) initiatives in improving the overall adoption of surgical robotics technologies 2. To analyze the ongoing shifts in healthcare needs which are largely driving R&D developments and technology-enabled business models of established and new participants. 3. Strategic investments, technical partnerships, distributor agreements, and IPOs in surgical robotics industry is increasing. What are the strategic priorities of existing/new participants in developing the global market? 4. In addition to the above, this research service also offers insights covering an independent review of industry strategies that are unbiased. This research service also provides details of key industry contacts who also participated in this research. Fri, 28 Sep 2018 00:00:00 +0100 Technologies Enabling Smart Water Grid http://www.frost.com/prod/servlet/sublib/display-report.do?id=D86D-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D86D-01-00-00-00 Water shortage caused by the intensification of the impacts of climate change, population growth, and accelerated urbanization require immediate action on development of technologies for effective management of water supply and consumption. In addition, aging water infrastructure leads to water loss and increase in non-revenue water. Smart water grid technologies are a promising solution for resolving a growing number of critical global water challenges. The adoption of technologies such as sensors, data analytics, and smart meters in water distribution networks will allow to control water losses and its inefficient use, thus ensuring financial savings. The study focuses on the advantages of adopting smart water grid technologies, integration of information and communication technologies and meters, devices and processes. The study also provides information about latest achievements in the development of water monitoring and control, leakage detection and prevention technologies, as well as smart water metering integrated with ICT. Fri, 28 Sep 2018 00:00:00 +0100 Technologies Energizing Oncolytic Adenoviruses http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-8D-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-8D-00-00 This Genetic Technology TOE encompasses recent advances in oncolytic viral platforms, while outlining the overall impact of gene therapy. Furthermore, this TOE covers the overview, technological capabilities, IP trends, clinical trial snapshot, and strategic insights for Sagetis Biotech. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Gene therapy, oncolytic virus, adenovirus, Sagetis, Biotech, Viroshield, AdNuPARmE1A, Duchenne s muscular dystrophy (DMD), pancreatic cancer, rare diseases, SAG-101, pancreatic ductal adenocarcinoma (PDAC) Fri, 28 Sep 2018 00:00:00 +0100 Gene Editing and Gene Therapy Breakthroughs Propelling Mainstream Treatments http://www.frost.com/prod/servlet/sublib/display-report.do?id=D85E-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D85E-01-00-00-00 The drug approvals of Yescarta (axicabtagene ciloleucel), Luxturna (Voretigene neparvovec) and Kymriah (Tisagenlecleucel) have turned a leaf in the pharmaceutical chapter of gene therapy development. Currently, genetic disorders do not have satisfactory treatment outcomes. This is in part due to the inability of small molecule drugs and enzyme replacement therapies, usually prescribed for inherited diseases, to correct the root cause of the disorders. In other words, they are not corrective therapies. Gene therapy offers exactly what small molecule drugs and enzyme therapy therapies don't- they can offer corrective solutions for inherited disorders. A new wave of gene therapy breakthroughs can be expected to follow in the next few years after a two-decade long hiatus that witnessed very few proven gene therapy drug candidates. This potential in-flux of gene therapy candidates is due to the two fundamental factors. First, the refining and development of cutting-edge vector platform both by academia and by pharmaceutical industry. This has resulted in the widely used advanced Adeno-associated viral vectors and Lentiviral vectors, both of which are used according to the applicability. Second, the development of novel gene editing tools such as TALENs, Meganucleases, CRISPR/Cas along with the improvement of old techniques such as ZFNs have helped improve the translational capability of gene therapies currently in clinical development. In the following study, the development of gene editing tools as well as gene-transfer enabling vectors is traced over the last decade or so while also putting into perspective the number of gene therapy candidates currently in clinical development in addition to the various potential cures and satisfactory treatments that await patients affected by genetic diseases . Fri, 28 Sep 2018 00:00:00 +0100 Innovations in Hemodialysis Systems, Pulmonary Artery Pressure Sensors, Surgical Systems, and Bio-batteries http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-21-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D852-00-21-00-00 The latest edition of Medical Device TOE profiles innovations in hemodialysis systems, pulmonary artery pressure sensors, surgical systems, and bio-batteries. Some of the innovations profiled include a portable hemodialysis system, an implantable pulmonary artery pressure sensor, a dynamic surgical guidance system for spine procedures, tissue-sparing surgical equipment for cervical spine fusion, a personalized diagnostic system to prevent antibiotic misuse, and a paper-based bio-battery for healthcare diagnostics. The Medical Device TechVision Opportunity Engine (TOE) analyzes and reports on new and emerging technologies and advances in R&D; product development; and regulatory matters related to neurology, ophthalmology, respiratory/anesthesia, wound care and management, surgical tools and instrumentation, drug delivery, orthopedics, endoscopy, cardiology, and monitoring. Medical devices and imaging technology and innovation research covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies, and imaging technologies and platforms. Keywords: Portable hemodialysis system, pulmonary artery pressure sensors, surgical systems, bio-batteries, dynamic surgical guidance system, personalized diagnostic system, antibiotics Fri, 21 Sep 2018 00:00:00 +0100 Novel Therapeutics for Duchenne Muscular Dystrophy http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-8C-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-8C-00-00 This Genetic Technology TOE depicts life sciences trends in therapeutics for Duchenne's musculrar dystrophy. The topics covered range from gene editing approaches to breakthrough muscle-on-a-chip innovations. Clinical trial analysis of important investigational therapeutics for Duchenne muscular dystrophy is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Duchenne muscular dystrophy, CRISPR-based therapeutics, muscle-on-a-chip platform Fri, 21 Sep 2018 00:00:00 +0100 Global Biologics Contract Development and Manufacturing Organization (CDMO) Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MC9B-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MC9B-01-00-00-00 The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global biologics Contract Development and Manufacturing Organization (CDMO) landscape with an emphasis on the key trends and growth opportunities across the global biologics outsourcing market. It also highlights the shifting focus and investments of pharma/biotech participants toward BioCDMOs for innovative biologics discovery, development, and manufacturing. With the changing market landscape, BioCDMOs are shifting toward providing value-added services by establishing themselves as a one-stop-shop for their pharma clients. These companies are adopting advanced manufacturing technologies such as single-use/disposable bioreactors, continuous, POD manufacturing, and so on with the integration of IT-based solutions implementing the Industrial Internet of Things (IIoT) by means of strategic collaborations and partnerships. Larger participants are resorting to Mergers and Acquisitions (M&As) in order to gain specific therapeutic and technical expertise from smaller, niche BioCDMOs. While the US and Europe are key markets, the outsourcing trend is slowly shifting toward APAC with several new entrants providing cost-effective drug development services.--BEGIN PROMO--

Research Scope

The study aims at identifying some key growth opportunities such as biosimilars co-development, designer cell lines, bioanalytical development and services, and so on that are set to drive the market over the next 5 years. It provides revenue forecasts of the global BioCDMO market as well as a breakdown by type of cell culture (mammalian versus microbial) and service type (drug substance verus drug product). The study highlights some of the key market drivers and restraints that will affect the overall growth of the market. Additionally, it provides an insight into leading disruptive technology trends such as improvements in upstream and downstream technologies, advances in lyophilisation, and increased application of Process Analytical Technologies (PAT) that are shaping the future of the BioCDMO industry. The study also highlights some emerging business models such as expanding services of CMOs into early stage of drugs, emergence of virtual biotech, out-licensing, and risk sharing between pharma and CMOs that are disrupting traditional business models.

Key Issues Addressed

  • Is the biologic contract manufacturing market growing, how long will it continue to grow and at what rate?
  • What are the fastest growing segments of the biologics contract development and manufacturing market?
  • What growth opportunities exist in the biologics contract development and manufacturing industry?
  • What are the key drivers and restraints affecting the growth of CDMOs?
  • What are the key challenges that CDMOs are likely to face in the near and long-term future? How can CDMOs strategize to overcome these hurdles?
  • In what ways is the biologics contract manufacturing industry likely to change to meet industry trends and dynamics?
  • Which are the game-changing companies and what are the disruptive technologies and business models? How do CDMOs position their assets with pharma companies?
Wed, 19 Sep 2018 00:00:00 +0100
Mammography Computer Aided Detection (Mammo CAD) Market in Western Europe, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MDD7-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MDD7-01-00-00-00 This insight presents an analysis of the mammography CAD (computer aided detection) market in Western Europe. It provides an in-depth analysis of the current trends, market size, revenue forecast, market penetration and market attractiveness, both in the two dimensional (2D) and three dimensional (3D) CAD markets. X-ray Mammography is the gold standard for breast cancer detection. With rising incidence of breast cancer, organized population based screening programs are carried out in Western countries at 1-3 year screening intervals, depending on the policies of individual countries. Starting early 1990s, countries in the region have witnessed a significant decrease in mortality. Mammography was not considered patient friendly due to the discomforts caused, possible false positives, failure to detect tumors and the potential radiation exposure. However, with innovations in technology, most western countries have switched to digital screening. Yet, the use of CAD is low in Western European countries and the guidelines prescribe double reading by radiologists for mammography interpretation. CAD algorithms aid in the diagnosis and visualization of mammography data. They process 2D and 3D tomosynthesis mammography images and identify regions of interest in breasts. With the advent of private hospitals and favorable health insurance reimbursements, there is more demand for patient safety and quality of technologies, reduced hospitalization and a reduction in the overall healthcare costs. Business models focusing on managed services, pay per use, sharing services, integrated workflow and automation are changing the procurement landscape of mammography CAD solutions. These factors determine the growth of the mammography CAD market.--BEGIN PROMO--

Research Scope

Market trends (Unit shipment of mammography and mammography CAD, Statistics on breast cancer procedure volume, radiologists, radiologists performing mammography, potential for 2D and 3D mammography CAD adoption, growth indicators, market adoption and penetration by country, potential adoption by hospital settings, key drivers and restraints for each country, factors influencing return on investment, forecasts, pricing trends, future prospects, competitive structure, market metrics, market share, revenues, strategy).

Regional Trends

  • Europe: Western Europe (Germany, The United Kingdom, Italy, France, Spain, Benelux (Belgium, Netherlands, Luxembourg), Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden))

Analysis by 2D and 3D Mammography CAD by countries is provided.

Market measurements are analyzed for the year 2017 and forecast up to 2022 – Revenue and Year-on-Year growth rate by countries and segments. Pricing range and growth trends by sub-segment for the base year are discussed.

Strategies, growth analysis, competitive landscape, and future focus are discussed for vendors (prominent among which are GE Healthcare, Siemens Healthineers, Hologic, IMS, Planmed, Fujifilm, ICAD and Screen Point).

Mon, 17 Sep 2018 00:00:00 +0100
RNA Technology Driving the New Wave of Therapeutics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-21-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D951-00-21-00-00 This Drug Discovery TOE depicts trends across RNA technology driving a new wave of therapeutics. Different, stable, non-Immunogenic mRNA therapies, targeted RNAi technologies and therapeutics, CAR T-cell therapy, antisense therapeutics, RNA-based delivery platforms, and DNA-directed RNAi approaches are discussed in the TOE. Clinical trials of HIV vaccines is also depicted. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest developments in drug discovery and therapeutics, thereby providing an opportunity to acquire strategic insights into crucial developments in this industry domain. Technologies profiled include those used for biomarker and target discovery such as high throughput screening, signal transduction, micro array, RNAi, metabolomics, toxicogenomics, biosensors and nanotechnology. In addition to these, a fair focus shall be dedicated to the latest trends in therapeutic approaches across a diversity of diseases including infectious, genetic, metabolic, neurological, cardiac, and autoimmune disorders. The Health and Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Targeted RNAi technology, enhanced disease management, non-immunogenic mRNA therapies, antisense therapeutics, RNA therapy, delivery platforms, DNA-directed RNAi approach, CAR T-cell therapy Fri, 14 Sep 2018 00:00:00 +0100 Medical Technologies Transforming the Future of Healthcare http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-8B-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-8B-00-00 This Genetic Technology TOE depicts life sciences trends across medical genetic technologies. Particular emphasis is focused on tissue regeneration and gene editing technologies. Clinical trials of stem cells is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Tissue regeneration, gene editing, Axolotl model, cardiovascular regeneration, artificial womb environment, stem cells Fri, 14 Sep 2018 00:00:00 +0100 Conventional Medical Imaging Modalities Facing Disruption http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298745130 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298745130 Fri, 7 Sep 2018 01:33:25 +0100 Movers & Shakers Interview with Steve Forcash VP, Solutions Management & Analytics at Discovery Health Partners http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298745122 http://www.frost.com/prod/servlet/sublib/display-market-insight.do?id=298745122 Fri, 7 Sep 2018 01:27:19 +0100 Explainable Artificial Intelligence for Drug Discovery and Development http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-8A-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-8A-00-00 This Genetic Technology TOE encompasses recent advances in artificial intelligence platforms enabling drug discovery and development, while highlighting the importance of explainability in AI-driven technologies for healthcare. The TOE also provides an overview of the AI value chain. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Explainable artificial intelligence, drug discovery, machine learning, Natural Language Processing, NLP Fri, 7 Sep 2018 00:00:00 +0100 Digital Transformation in the Pharmaceuticals Industry Companies-to-Action, 2018 http://www.frost.com/prod/servlet/sublib/display-report.do?id=ME1D-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=ME1D-01-00-00-00 The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers digitally enabled by the entry of non-traditional tech companies such as Apple, Facebook, and Google pushing pharmaceutical companies to go beyond-the-pill. However, in the midst of this chaos, there are pioneering companies offering solutions that apply cutting-edge digital technologies such as AI, Big Data and analytics, cloud, mobile, blockchain, and Internet of Things (IoT) to build digital convergence across the pharmaceutical value chain, covering R&D, manufacturing and operations, marketing, and patient connect. This Companies to Action (C2A) analysis puts the spotlight on such game-changing, tech-enabled participants and how they are altering the status-quo by highlighting novel monetization models and strategic investment opportunities.--BEGIN PROMO--

Research Scope

The key objective of this study is to highlight current market dynamics, key market participants, customer segments, and evolving business opportunities. The study aims to identify pioneering companies that are capable of shaping the future through best practices implementation, visionary leadership, and innovation in business models. The company profiles offer insights around key solution offerings, target customer segments, service differentiators, and future growth strategies.

Further, the global study provides an analysis of companies segregated by market segments such as: smart R&D, flexible manufacturing, connected patients, and digital pharmacy. The analysis covers technologies such as Artificial intelligence (AI), Big Data and analytics, crowdsourcing, mobile, Industrial IoT (IIoT), IoT, cloud, blockchain, eCommerce, and so on.

The participants mentioned in the study are iSolve, Zephyr Health, PillPack, Proteus Digital Health, BenevolentAI, Elemental Machines, Exscientia, Science 37, Transparency Life Sciences, and uMotif. It also lists the wider universe of companies that were assessed for this analysis. These companies were chosen based factors such as innovative technology development and application, hitting the right focus areas, proven success and industry recognition, and enhanced client collaborations.

Key Issues Addressed

  • How are companies creating extraordinary value for pharmaceutical stakeholders?
  • Which are some unique companies that are introducing new and innovative solutions in the market?
  • How do these companies intend to transform the healthcare industry paradigms in the future? What is the impact of the external industry environment on this market?
  • What is their action plan and potential for growth? What are the current growth opportunities in digital transformation?
  • What are some key success factors in the pharmaceutical market?
  • Which are the companies with whom partnerships can be forged?

 

Tue, 4 Sep 2018 00:00:00 +0100
Advancements in Microalgae, Machine Learning, Acoustic Systems, and RNAi Therapeutics http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-89-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-89-00-00 This edition of the Inside R&D TOE depicts the current landscape and the new trends in microalgae and biofuel production, machine learning system for 3D printing quality monitoring. It also focuses on innovations in acoustic systems and RNAi therapeutics for precision medicine advances. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Microalgae, biofuel, 3D printing, machine learning, RNAi, acoustic, precision medicine Fri, 31 Aug 2018 00:00:00 +0100 Innovations in Drug Delivery, Cancer Immunotherapies, Biomarker Identification, and Gene Therapy for Preventing Vision Loss http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-89-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-89-00-00 This Genetic Technology TOE depicts life sciences trends across drug delivery platforms, cancer immunotherapies, biomarker identification, and gene therapy. Among the therapeutic areas in focus, age-related macular degeneration (AMD), aggressive childhood cancers, and bladder cancer, are of note. Clinical trial analysis of recombinant drugs for different forms of cancer is also presented. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Drug delivery, cancer immunotherapies, biomarker identification, gene therapy, vision loss, age-related macular degeneration, aggressive childhood cancers, bladder cancer Fri, 31 Aug 2018 00:00:00 +0100 Growth Insights for the Direct-to-Consumer Genetic Testing Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K2F1-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K2F1-01-00-00-00 As healthcare evolves toward personalized solutions, everyday consumers are proactively taking responsibility for their health in ways unimaginable a decade ago. A direct-to-consumer genetic test (DTCGT) exemplifies this trend which can be purchased and used directly by consumers without the requirement of a prescription from a healthcare provider. The tests can be purchased online from distribution channels such as DTCGT company websites, e-commerce channels, and online pharmacies. Challenges faced by the industry include unclear regulations, lack of standard guidelines, low test margins, concerns related to scientific validity and consumer data privacy. However, drivers such as increased consumer awareness, approval of health risk genetic tests in the United States, development of significantly modified tests with robust scientific validation and data monetization collaborations with stakeholders such as pharmaceutical companies have provided a strong impetus to the growth of the DTCGT market. With the synergistic effect of advanced technologies such as Artificial Intelligence, Big Data Analytics, and Blockchain on the traditional genetic testing market, along with the adoption of novel distribution models, the market growth is anticipated to increase dramatically in the next five years.--BEGIN PROMO--

Research Scope

The key objective of the growth insights on the DTCGT market is to highlight current market dynamics such as key market participants, market segments and evolving business opportunities. The study aims to identify both established enterprises and start-ups, which are capable of shaping the future through best practices implementation, visionary leadership, and innovation in product offerings. Further, the study provides an analysis of market sizing by revenue segregated by ancestry genetic tests, health risk genetic tests and lifestyle genetic tests. It covers the key drivers, challenges in the market impeding growth, competitive landscape, market participant strategies and future growth strategies. The study also highlights growth opportunities, key trends, mergers and acquisitions, novel distribution models, geographical lucrativeness, notable partnerships, investor funding, collaboration opportunities and key companies to watch. The study is global with deep dives for North America, Europe, Asia Pacific, Middle East and Africa.

Major participants mentioned in the study are 23andMe, Ancestry, National Geographic Geno 2.0, Helix, Mapmygenome, Atlas Biomed, MyHeritage, 23mofang, EasyDNA and DNALabsUAE.

Key Issues Addressed

  • How attractive is the DTCGT market? Which segments are anticipated to grow in the future and their market? 
  • What are the factors driving the demand for DTCGT? What are the business and distribution models that will affect the market?
  • What will be the focal areas of application of technology? Which emerging regions are more lucrative than others?
  • What are the factors impacting solution providers? What are the market dynamics around the key trends as well as market drivers and restraints?
  • Which are the game-changing companies at work? What are the strategic levers to stay on the growth trajectory?
  • What are the key growth opportunities and investment recommendations in this space?
Mon, 27 Aug 2018 00:00:00 +0100
Digital Innovations Transforming Healthcare http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-88-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D758-00-88-00-00 This Genetic Technology TOE depicts life sciences trends across digital innovations, including, digital genomics and artificial intelligence (AI)-driven medicine. Clinical trials for Propeller Health Platform is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Digital innovations, digital health, digital genomics, digital platforms, digital medicine, artificial intelligence (AI), AI-enabled healthcare Fri, 24 Aug 2018 00:00:00 +0100 Innovations in Hydrogen Production, Neural Cell Implants, Solar Panel Recycling, Artificial Intelligence, and Ophthalmology http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-88-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D707-00-88-00-00 This edition of the Inside R&D TOE depicts developments associated with hydrogen production and neural cell implants. It also focuses on innovations in solar panel recycling, artificial intelligence, and ophthalmology. Inside R&D TechVision Opportunity Engine (TOE) covers global innovations that are in research and development in virtually all technology areas. We provide intelligence and insights on innovations spanning a wide variety of industry areas, including automation, electronics, sensors, information and communication technologies, manufacturing, health, wellness, medical devices, pharma, biotechnology, materials, coatings, renewable fuels, automotive, power systems, sustainable energy solutions and innovations that contribute to a cleaner and greener environment. Keywords: Water splitting, electrocatalyst, spinal cord, solar recycling, ophthalmology Fri, 24 Aug 2018 00:00:00 +0100 Artificial Intelligence Market Key Application Areas for Growth in Healthcare IT, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K26D-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K26D-01-00-00-00 The study describes how AI technologies are paired with legacy healthcare IT systems to deal with the complexity & growth of medical data. Frost & Sullivan acknowledges that AI intuitively finds ways to convert these ever-expanding resources into actionable evidence for end users. In this study, Frost & Sullivan has forecast global revenue for primary healthcare IT segments* which leverage AI to augment product functionalities. Additionally, the study also features and assesses various progressive AI vendors, offering visionary capabilities that strive to normalize disparate patient data, apply scientific algorithm to generate healthcare evidences and drive cognitive reasoning to predict population health outcomes. The global market revenue has been classified by these end users' corporate receptivity, behavioral agility, and financial ability to fund and sustain AI-enabled HC interventions that promise better outcomes for all. Democratization of AI is on the horizon, which may disrupt the way healthcare has been perceived and delivered. Today, AI-powered digital health solutions primarily allow healthcare enterprises to predict, automate, and prescribe evidence-based business decisions. However, AI-powered digital health solutions from technology maturity and real-word applicability standpoint are still in their infancy. Hence the technology penetration across all end users is low to moderate. It has been estimated that at present only around 20% of these end users would be actively using AI to drive real change in the way healthcare has been conceived and delivered. However, as leading IT companies such as IBM Watson Health, Google, Amazon, Microsoft, Philips, GE Healthcare and Salesforce have started to offer impeccable cloud services and tools to independent AI software developers, more progressive applications, capable of ensuring tangible ROI to end users would flourish and drive the overall market penetration for these technologies. Big-Tech is taking the lead to catalyse innovation in the healthcare AI market. Google is primarily using AI to source and normalize EHR data to identify disease patterns that were historically untraceable. IBM continues to grow its presence in healthcare, driven by a focus on AI-powered clinical decision support, imaging analytics and population health management through its Watson Health business. Additionally, Amazon is making inroads into various aspects of healthcare AI (and could make a big move voice applications, cloud infrastructure solutions and visionary research works) or several big moves-- in this year. Major EHR companies are committing to reduce physicians IT burden by incorporating AI-enabled and voice based medical assistants into their incumbent EHR workflows. Epic recently announced that it has integrated Nuance s AI-powered virtual assistant platform into its EHR. Functionalities include the ability for clinicians to ask for lab results, medication lists, visit summaries and other information in the Epic Haiku mobile app. Athenahealth is also partnering with progressive start-ups that help physicians automate the process of patient scheduling, clinical documentation and coding. Putting Patient Data into Work is a Critical Perquisite of Success for AI-powered health IT solutions. Big-tech must acknowledge that patient generated data which next-generation IT platforms interpret has multiple utilities for diverse healthcare stakeholders. Fully informed consent from patients coupled with 100% compliance with stringent data usage regulation has to be ensured to remain relevant in the market. Frost and Sullivan s new research report on Artificial Intelligence Market Key Application Areas for Growth in Healthcare IT provides a comprehensive analysis on the global healthcare AI market which is primarily segmented into three service verticals that embrace a range of AI technologies to modernize care, personalize treatment and improve outcomes for key end users. Key Regional Markets, Covered in the Research Study The United States of America The United Kingdom France Germany China Switzerland Japan India Types of AI Products Discussed in the Report SaaS Based App Based Integrated Hardware Research-based Doctor-facing Patient-facing Telehealth Key Service Segments (Vendors are Selected by Sub-Segments), covered in the Research Study* Clinical Applications EMR Clinical Decision Support Systems Clinical Analytics Imaging IT Precision Medicine/Genomics IT Wearable Femtech Mental Health Patient Engagement Population Health Management Telehealth Operational Applications Administrative Management Supply Chain Management Enterprise Content Management Cybersecurity Financial Applications Business Intelligence Revenue Cycle Management Coding and Claims Management Key Disease Categories, covered in the Research Study Cancer Cardiology Diabetes Endometriosis Infectious Diseases Rare Diseases *Adoption of AI for the pharmaceutical market, as it relates to digital health, is also discussed but is not included in the market revenue numbers.--BEGIN PROMO--

Key Issues Addressed

  • What are the regional market trends and industry dynamics in global AI for healthcare IT market? What is the future potential for AI-powered healthcare IT solutions? 
  • What is the current market scenario? How much growth is expected? Which are the major market segments? What will be the impact of external trends on each business segment? 
  • Who are the major participants in the global AI for healthcare IT market? What and how are they innovating in this space? 
  • What are the important business model considerations (penetration, pricing and profitability information) for healthcare stakeholders and providers? Who should pay for healthcare AI products? Is there an untapped opportunity in this market?
Fri, 24 Aug 2018 00:00:00 +0100
Innovations in Ultrasound Imaging, Image Guidance, 3D Imaging, Endoscopic Imaging, and Artificial Intelligence for Healthcare Imaging http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-23-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D861-00-23-00-00 The latest issue of Medical Imaging and Diagnostics TOE profiles innovations in the medical imaging and diagnostics industry. Some of the profiles covered include development of accurate detection of eye disease using artificial intelligence platform, a sensor for monitoring cancer therapeutic response, a blood test for early detection of renal cancer, a nano-optic endoscopic imaging catheter for efficient tissue imaging, wearable ultrasound imaging device, machine vision-based image guidance for cranial surgery, and holotomography microscopy for label-free 3D imaging of live cells. Medical Imaging and Diagnostics TechVision Opportunity Engine (TOE)'s mission is to analyze and report new and emerging technologies; advances in R&D, product development and regulatory matters specifically related to the areas of CT, MRI, NM, PET, Ultrasound and X-ray. In addition, relevant developments in fusion technologies, functional imaging technology, interventional cardiology and image guided surgery and healthcare IT related areas such as PACS, medical information storage, and disaster recovery/business continuance will also be covered. The Health and wellness cluster covers cutting-edge global developments in medical devices and imaging sectors such as biosensors, biomaterials, biomechanics, microtechnologies, nanotechnologies, assistive technologies and imaging technologies and platforms. Keywords: Nano-optic endoscopic imaging, machine vision-based image guidance, automated medical image analysis, wearable ultrasound imaging, artificial intelligence, holotomography microscopy, 3D live cell imaging Fri, 24 Aug 2018 00:00:00 +0100 Western European Clinical Laboratory Services Market, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MDFC-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MDFC-01-00-00-00 Diagnostics has inarguably become an integral part of healthcare system, moving from reactionary science to predictive science; playing a vital role throughout the care continuum. While rising burden of chronic diseases, drug-resistant diseases and the increasing proportion of elderly population are the organic growth drivers, the shift towards creating individualized treatment plans and evolution of personalized drug discovery have been the largest inorganic growth contributors. Key service providers in this study are segmented into independent reference labs (IRLs), physician operated labs (POLs) and hospital labs. At the sub-segment level, this research study covers the shifting dynamics between these service providers including outsourcing and overall testing trends. The study also captures the additional play between the cash-strapped public and the technology-rich private sector. While there has been exponential growth in demand for diagnostic services, there is a constant pressure to do so under budget and skill constraints. This has led to the rise of new technologies which are not only pushing the envelope on sensitive, rapid and accurate testing but are also affordable and bring down the cost of the total treatment cycle. This study identifies some of the key technology trends and growth opportunities, which are set to drive the market in the next five years. In conjunction with technological evolution, the study additionally highlights new and emerging business models that have enabled certain companies to succeed in this incrementally competitive market. It also gives an overview of the competitive environment, providing brief insights on some of the game-changing as well as emerging players which have the potential to unlock growth in this market. The market continues to remain fragmented but larger players have managed to gain size and growth through acquisitions. Therefore, the study also focuses on some of the leading M&A activities impacting the market as well as present and future market trends which would shape the market. Acknowledging the ongoing regulatory restructuring in Europe in the form of IVDR, GDPR, and Digital Single Economy, the study analyzes the impact of these changes on the market in the near as well as long terms. As Europe collectively progresses toward a more stringent compliance regime, companies need to realign their operational blueprints. The study lays down strategic imperatives for companies to recalibrate their business models and be future ready. This research service also provides in-depth revenue and geographical market analysis of three key market regions, EU5, Benelux and Scandinavia, identifying the impact of new regulatory and reimbursement trends in each country.--BEGIN PROMO--

Key Issues Addressed

  • What are the regulatory, legislative, and policy challenges? How will these impact the different stakeholders in the diagnostic healthcare ecosystem?
  • Which are the new disruptive technologies and what is the degree of new technology adoption? What are the key enablers and barriers to entry?
  • How are the business models evolving and expanding beyond conventional horizons? Are these business models sustainable in the long run?
  • Which geographies are primary growth drivers? How is the changing economic scenario affecting the regional market?
  • Who are the key participants in this heavily fragmented market? Which are the game-changing companies at work?
  • How will the competitive landscape change with time? Will the market continue to remain lucrative for mergers and acquisitions?
Thu, 23 Aug 2018 00:00:00 +0100
Western European Endoscope Reprocessing Systems and Software Solutions Market Assessment, Forecast to 2022 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MDB8-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=MDB8-01-00-00-00 Endoscope reprocessing systems and workflow solutions was a 416.4 million market in the top five Western European countries (UK, Germany, France, Spain, and Italy) in 2017. It is expected to grow at a robust CAGR of 9.5% to reach a revenue of 654.9 million by 2022. The market is segmented into two broad segments which are then divided into several subsegments as mentioned below: Endoscope reprocessing solutions Core equipment o Automated Endoscope Reprocessors (AERs) o Storage and Drying Cabinets for Consumables o Disinfectants and Chemicals o Detergents Support Products o Scope Transport Carts (Trays and Trolleys) o Flushing Sinks o Test Strips o Cleaning Products (Wipes, Sponges, Brushes) Workflow solutions Integration Software Solutions Track and Trace Solutions The growth in AER revenue in EU-5 is driven by system replacements, owing to historically high levels of installed bas,e coupled with slower capacity expansion and newer hospital construction. Replacement sales for AERs held 63.4% share in 2017 which is expected to remain stable and account for 63.2% in 2022, indicating a near-equal increase in both replacement and new installation revenue during the forecast period.--BEGIN PROMO--

EU-5 countries have been effectively moving towards a day-care based healthcare system over the past decade. This is evident in the fact that majority of endoscopy procedures in the region are conducted in day-care facilities, which accounted for 56.3% of total endoscopy procedural volume in EU-5. The trend is expected to further strengthen during forecast period, with day-care based endoscopy procedures growing at a faster CAGR of 6.6% as compared to hospital procedures, which will grow at 5.1% during 2017-2022. Consequently, the former’s share of procedural volume will grow from 56.3% in 2017 to 58.0% by 2022.

Healthcare watchdogs across EU-5 countries have been pushing for reduced endoscopy wait times amidst expected increase in procedural volume pressures on existing facilities. This has led to requirements of greater inventory of endoscopes and hence, greater need for specialized storage and drying systems to enhance scope storage times, reduce chances of re-contamination of stored endoscopes thus reducing unnecessary reprocessing requirements as well as enable on time readiness of endoscopes for patients.

While, the number of day care facilities has increased in EU-5, the market has not shown a proportionate growth in newer unit shipment of AERs, as is evident from the near-equal growth in replacement and new installation. This is due to the fact that a comparatively lower proportion of European day-care facilities have their own decontamination units. The ratio of the number of endoscope decontamination facilities to the number of day-care facilities in EU-5 is estimated to be around 0.44, indicating 1 decontamination unit for every 2.5 endoscopy units. The ratio has been found to be around 0.55 for countries such as the US. The lower number of decontamination facilities in day-care units, indicates higher prevalence of outsourcing of reprocessing loads to bigger neighboring facilities. Additionally, an uptick in commercial outsourcing of endoscope reprocessing over the past 2–3 years, has led to a further decrease in the need for an already size-restricted day-care facility to have its own decontamination facility.

An alternative trend is the rise in the number of big, technology-laden “Mega Hospitals” in Europe, coupled with the increasing consolidation of hospital systems across these countries. This has led to financially strong and operationally stable entities that are willing to invest in cutting-edge next-gen technologies with proven records of cost and efficiency savings and enhancement of staff and patient experience. This trend has led to mentionable adoption of various newer technologies such as automation, robotics, and advanced digital technologies into CSSDs and reprocessing departments leading to greater evolution of the overall market.

Wed, 22 Aug 2018 00:00:00 +0100
Future of Electronic Medical Record and Electronic Health Record in Asia-Pacific, Forecast to 2023 http://www.frost.com/prod/servlet/sublib/display-report.do?id=PA17-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=PA17-01-00-00-00 The governments and providers in Asia-Pacific (APAC) are focused on reducing medical expenses while improving population health and well-being. A shortage of medical professionals is seen across multiple specialties in various APAC countries; moreover, clinicians are concentrated in urban areas leading to disproportionate clinician to-patient ratios in many areas. To address these challenges, APAC has been investing in healthcare digitalization to increase efficiency, reduce expenses, and automate/eliminate redundant processes. As a result, the adoption of IT is spurring a new wave of development across both public and private hospitals in APAC. The most notable of the IT upgrades are the Electronic Medical Record (EMR) and Electronic Health Record (EHR) technologies. On one hand, an EMR is a legal, digitized record of all encounters an individual has with a particular healthcare provider, supported by one or more of the following applications: clinical data repository (CDR), clinical decision support system (CDSS), controlled medical vocabulary (CMV) and/or computerized physician order entry (CPOE). On the other hand, an EHR is a legal, digital record of all encounters that an individual has with possibly all the healthcare provider organizations within a community, state, or region. This research identified the growing emphasis on patient experience, increasing emphasis on evidence-based care, increasing demand for Population Health Management (PHM) and competition amongst healthcare providers as the top four industry transformations driving EMR and EHR adoption in this region. According to HIMSS APAC, 42 hospitals in the region have achieved Stage 6, and 8 hospitals have achieved Stage 7. More hospitals are moving in the same direction. However, significant investments in EMR, particularly from the public sector, have received widespread criticism from APAC due to the below-expectation returns that they have generated in the past. A key reason for this is the inadequate integration of diverse systems and lack of attention to system interoperability. Therefore, despite investing in the best of solutions healthcare, providers are unable to reap the benefits because they are not able to streamline workflows and gain efficiencies in organizational processes. System interoperability has emerged as a top priority amongst several governments and efforts are being made in this direction by governments, not-for-profit organizations and the private sector. This research also identified poor user interface, cost management and lack of robust training as the top challenges and unmet needs amongst healthcare providers. The report also suggests potential solutions that the EMR/EHR vendors can consider to address the emerging market needs. New technologies such as telehealth, artificial intelligence, and open API continue to make way into the healthcare systems as they hold potentials to further improve clinical and operational efficiencies. These technologies are either capturing clinically significant patient data or leveraging patient data for analysis; both require seamless integration with the EMR/EHR systems. Market development across APAC has been extremely uneven and countries stand at varying levels of adoption and sophistication of EMR and EHR. While developed nations such as Australia, Singapore, Japan, Hong Kong are exploring solutions that help analyze health data to support predictive population health management, developing markets such as Malaysia, Indonesia and Thailand are still focusing on improving their information capture systems.--BEGIN PROMO--

Research Highlights

This report identified key trends shaping the future EMR /EHR market in this region as well as in individual countries and highlight growth opportunities for EMR/EHR vendors. The private sector in APAC will continue to present greater potential as it has the budget to invest in innovative EMRs. Private hospitals will invest in providing high-quality care enabled by technology to attract patients. Japan and China present the greatest opportunity, followed by Australia. These countries are innovating in this space and have a high number of hospital base. South Korea contributes the highest percentage of regional revenue concentrated with local players and it has stringent regulation on data sharing outside of the hospital.

Key Conclusion

In the next 5 year, EMR vendors in APAC will compete by offering different EMR software packages for developed and developing nations: highly scalable and affordable EMR packages for developing nations and sophisticated EMR packages for developed nations.

Tue, 21 Aug 2018 00:00:00 +0100
Artificial Intelligence for Medical Image Analysis Companies-to-Action, 2018 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K27C-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=K27C-01-00-00-00 Medical imaging has become the bellwether application for artificial intelligence (AI) technologies in healthcare. From deep learning and machine learning approaches, to cognitive computing, to even natural language processing, several AI approaches are now being incorporated in the field of radiology. Apart from academic research groups, almost all major manufacturers and vendors in the medical imaging space have or are developing initiatives to bring automation, augmentation or acceleration to medical imaging, cognitive computing for imaging informatics applications and even intelligent machines. There are several startups as well which continue to advance the development of solutions. In the medical imaging workflow, from ordering of imaging studies all the way up to follow-up post imaging, artificial intelligence could play a role. Of course, current efforts are mostly concentrated in analyzing the medical images. These solutions have been deployed on premises, but there is a gradual adoption of cloud technologies too. As applications evolve and are developed further, AI is moving to the edge, and might also become embedded in imaging equipment as the next frontier. However, at the global level, countries look up to AI to address very different and systemic challenges while some such as the United States require higher productivity and standardization, the United Kingdom needs to address shortages and higher wait time, whereas others such as China need it to build access and expertize to improve diagnosis rates. This has naturally resulted in a continuous growth in the number of startups emerging in this field, globally. Funding too, has flowed in to support the momentum. Crucial regulatory milestones have been achieved, but many more are likely to be reached as well. This study is a focused analysis to highlight all of the companies active in this space, and to analyze their solutions to get a sense of the trends in the industry. Aptly called the Companies-to-Action, a comprehensive analysis of ~100 AI companies currently offering medical image analysis solutions provides an in-depth insight in to several key questions, as outlined below. Competitive landscape, evolving partnerships, regional analysis to identify conducive factors for development of AI solutions, funding trends for the 80+ startups, a landscape assessment, and finally, a list of top ten predictions for the coming 5 years are covered in this study. It also highlights a curated list of companies along with our perspective on their uniqueness, potential opportunities, and threats.--BEGIN PROMO--

Key Issues Addressed

  • Who are the companies that have set out to develop and commercialize artificial intelligence-based solutions for medical image analysis?
  • Which modalities, organs and disease areas have vendors focused on during the inception phase 2011-2018?
  • What kind of competitive and partnership dynamics are taking place across the vendor, provider and investor ecosystems?
  • What are some unique approaches and use cases addressed by some of the most innovative companies vested in AI-based medical image analysis?
  • How do various regions fare in the adoption of, and investment in AI based technologies for medical image analysis?
Tue, 21 Aug 2018 00:00:00 +0100
3D Printing Revolutionizing Medical Device Manufacturing http://www.frost.com/prod/servlet/sublib/display-report.do?id=D845-01-00-00-00 http://www.frost.com/prod/servlet/sublib/display-report.do?id=D845-01-00-00-00 Healthcare 3D printing is the next technology frontier in the healthcare industry. This field has shown its potential in recent years and remains as biggest breakthrough in healthcare industry. Slowly 3D printing will be evolved into a mainstream medical practice. Several types of 3D printing solutions have been created to benefit patients across various medical applications. The research service sheds light on various 3D printing technologies that are currently available and associated materials that can be used for various medical applications. This report is important for strategies that can be implemented by the market participants to address the currently available industry challenges. The analysis would be helpful for the new entrants and established market players to create value chain that enables the production of 3D printed medical devices with great efficiency at affordable costs.--BEGIN PROMO--

3D printing is revolutionary in serving the huge demand or requirement for varied types of organs globally. 3D printing is a wave for the advancement of healthcare industry by providing various medical devices or organ for various applications and affordable prices. Opportunities will open up for various medical application due to the customizability in design and size of the medical device. 3D printing has proved to have immense applications in personalized healthcare. 

Mon, 20 Aug 2018 00:00:00 +0100